From this small study, the subtypes of patients with TNBC who are most likely to respond to olaparib treatment could not be evaluated; however, responses to olaparib have been seen in previous studies of patients with breast and ovarian cancers with germline BRCA1 and/or BRCA2 mutations, as well as patients with high-grade serous ovarian cancers, suggesting that there is a subgroup who will be likely to benefit [12-14]. This evidence concerns the gene BRCA2 and ovarian carcinoma.